|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
First published online 9 January 2008
doi: 10.1242/dev.009910
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
in prostate development, regeneration and tumorigenesis
1 Center for Cancer and Stem Cell Biology, Institute of Biosciences and
Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd.,
Houston, TX 77030-3303, USA.
2 Department of Surgery, University of Western Ontario, London, ON, N6A 4G5,
Canada.
3 Departments of Medicine, and Genetics and Development, Columbia University,
College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer
Center, 1130 St. Nicholas Avenue, Room 217B, New York, NY 10032, USA.
4 Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100
Fairview Avenue, Seattle, WA 98109-1024, USA.
Author for correspondence (e-mail:
fwang{at}ibt.tmc.edu)
Accepted 24 November 2007
The fibroblast growth factor (FGF) regulates a broad spectrum of biological
activities by activation of transmembrane FGF receptor (FGFR) tyrosine kinases
and their coupled intracellular signaling pathways. FGF receptor substrate
2
(FRS2
) is an FGFR interactive adaptor protein that links
multiple signaling pathways to the activated FGFR kinase. We previously showed
that FGFR2 in the prostate epithelium is important for branching morphogenesis
and for the acquisition of the androgen responsiveness. Here we show in mice
that FRS2
is uniformly expressed in the epithelial cells of developing
prostates, whereas it is expressed only in basal cells of the mature prostate
epithelium. However, expression of FRS2
was apparent in luminal
epithelial cells of regenerating prostates and prostate tumors. To investigate
FRS2
function in the prostate, the Frs2
alleles were
ablated specifically in the prostatic epithelial precursor cells during
prostate development. Similar to the ablation of Fgfr2, ablation of
Frs2
disrupted MAP kinase activation, impaired prostatic
ductal branching morphogenesis and compromised cell proliferation. Unlike the
Fgfr2 ablation, disrupting Frs2
had no effect on the
response of the prostate to androgens. More importantly, ablation of
Frs2
inhibited prostatic tumorigenesis induced by oncogenic
viral proteins. The results suggest that FRS2
-mediated signals in
prostate epithelial cells promote branching morphogenesis and proliferation,
and that aberrant activation of FRS2-linked pathways might promote
tumorigenesis. Thus, the prostate-specific
Frs2
cn mice provide a useful animal model
for scrutinizing the molecular mechanisms underlying prostatic development and
tumorigenesis.
Key words: Adaptor proteins, Growth factors, Receptor tyrosine kinases, Prostate cancer, Mouse models